search icon
coya-img

Coya Therapeutics, Inc. Common Stock, Common Stock

COYA

NAQ

$5.65

-$0.32

(-5.36%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$94.40M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
61.90K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.75 L
$10.69 H
$5.65

About Coya Therapeutics, Inc. Common Stock, Common Stock

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCOYASectorS&P500
1-Week Return-8.43%0.31%-1.26%
1-Month Return-0.18%0.6%-4.16%
3-Month Return-27.93%-9.44%-0.46%
6-Month Return-26.62%-5.15%3.58%
1-Year Return1.07%0.33%22.47%
3-Year Return23.63%4.53%25.13%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue---6.00M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-16.13K27.36K27.36K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":58.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit-(16.13K)(27.36K)5.97M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.27,"profit":false},{"date":"2022-12-31","value":-0.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin-(Infinity%)(Infinity%)99.54%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses694.77K4.87M9.81M13.91M[{"date":"2020-12-31","value":5,"profit":true},{"date":"2021-12-31","value":35.02,"profit":true},{"date":"2022-12-31","value":70.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(694.77K)(4.87M)(9.81M)(7.90M)[{"date":"2020-12-31","value":-69477000,"profit":false},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":-981193900,"profit":false},{"date":"2023-12-31","value":-790334900,"profit":false}]
Total Non-Operating Income/Expense-(21.48K)--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-2148200,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(733.20K)(4.89M)(12.24M)(7.26M)[{"date":"2020-12-31","value":-73319500,"profit":false},{"date":"2021-12-31","value":-489179200,"profit":false},{"date":"2022-12-31","value":-1224477600,"profit":false},{"date":"2023-12-31","value":-726398400,"profit":false}]
Income Taxes(704.65)(21.48K)2.43M723.85K[{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":-0.88,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":29.75,"profit":true}]
Income After Taxes-(4.87M)--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations-(4.89M)(12.24M)(12.36M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-489179200,"profit":false},{"date":"2022-12-31","value":-1224477600,"profit":false},{"date":"2023-12-31","value":-1236147900,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(733.20K)(4.87M)(14.68M)(7.99M)[{"date":"2020-12-31","value":-73319500,"profit":false},{"date":"2021-12-31","value":-487031000,"profit":false},{"date":"2022-12-31","value":-1467761300,"profit":false},{"date":"2023-12-31","value":-798783600,"profit":false}]
EPS (Diluted)--(0.51)(0.79)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-51.24,"profit":false},{"date":"2023-12-31","value":-79,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

COYA
Cash Ratio 13.39
Current Ratio 15.31

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

COYA
ROA (LTM) -29.34%
ROE (LTM) -50.83%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

COYA
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

COYA
Trailing PE NM
Forward PE NM
P/S (TTM) 9.88
P/B 2.95
Price/FCF NM
EV/R 11.54
EV/Ebitda NM

FAQs

What is Coya Therapeutics, Inc. Common Stock share price today?

Coya Therapeutics, Inc. Common Stock (COYA) share price today is $5.65

Can Indians buy Coya Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Coya Therapeutics, Inc. Common Stock (COYA) on Vested. To buy Coya Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COYA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Coya Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Coya Therapeutics, Inc. Common Stock (COYA) via the Vested app. You can start investing in Coya Therapeutics, Inc. Common Stock (COYA) with a minimum investment of $1.

How to invest in Coya Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Coya Therapeutics, Inc. Common Stock (COYA) via Vested in three simple steps:

  • Click on Sign Up or Invest in COYA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Coya Therapeutics, Inc. Common Stock shares
What is Coya Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Coya Therapeutics, Inc. Common Stock (COYA) is $10.69. The 52-week low price of Coya Therapeutics, Inc. Common Stock (COYA) is $4.75.

What is Coya Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Coya Therapeutics, Inc. Common Stock (COYA) is

What is Coya Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Coya Therapeutics, Inc. Common Stock (COYA) is 2.95

What is Coya Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Coya Therapeutics, Inc. Common Stock (COYA) is 0.00%

What is the Market Cap of Coya Therapeutics, Inc. Common Stock?

The market capitalization of Coya Therapeutics, Inc. Common Stock (COYA) is $94.40M

What is Coya Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Coya Therapeutics, Inc. Common Stock is COYA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top